About ABUS

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ABUS is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 203.3 M 2.03268E+08 226 226 0.0% 4.56194E-05 20 K 20186
UBIO Proshares UltraPro Nasdaq Biotechnology 25.3 M 2.53416E+07 221 221 0.0% 2.28804E-05 2 K 1950
IBB iShares Nasdaq Biotechnology Index Fund 7.3 B 7.33377E+09 215 215 0.01% 0.0001 899 K 898553
IWC iShares Microcap ETF 810.8 M 8.10776E+08 1,386 1386 0.02% 0.0002 138 K 137623